Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(166 produits)
- Bcr-Abl(117 produits)
- EGFR(553 produits)
- FAK(72 produits)
- FLT(88 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(176 produits)
- JAK(243 produits)
- PDGFR(127 produits)
- RAAS(86 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(51 produits)
- VDA(2 produits)
- VEGFR(236 produits)
Affichez 6 plus de sous-catégories
2277 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
E7090 succinate
CAS :E7090 succinate inhibits FGFR1, FGFR2, and FGFR3 with IC50: 0.71, 0.50, 1.2 nM; less so FGFR4 at 120 nM.Formule :C76H92N10O24Couleur et forme :SolidMasse moléculaire :1529.60PP487
CAS :PP487 is a dual tyrosine kinase/PI(3)K inhibitor, exhibiting IC50 values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. It is applicable in cancer research [1].Formule :C14H14BrN5OCouleur et forme :SolidMasse moléculaire :348.2JAK2 JH2 binder-1
CAS :JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.Formule :C29H25N7O6SCouleur et forme :SolidMasse moléculaire :599.62MTX-216
CAS :MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.Formule :C22H14Cl2FN5O2SCouleur et forme :SolidMasse moléculaire :502.348EGFR-IN-38
CAS :EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96HG-7-86-01
CAS :HG-7-86-01 is a selective type II tyrosine kinase inhibitor with antiproliferative activity against mutant T315I- Bcr-Abl for chronic myeloid leukemia (CML).Formule :C28H21F3N6O2SDegré de pureté :99.07%Couleur et forme :SolidMasse moléculaire :562.57VEGFR-2/DHFR-IN-2
VEGFR-2/DHFR-IN-2 inhibits VEGFR-2 & DHFR (IC50: 0.623 & 9.085 μM), toxic to C26, HepG2, MCF7 cells (IC50: 3.59-8.38 μM), promising for cancer study.Formule :C21H21NO4Couleur et forme :SolidMasse moléculaire :351.4Hypothemycin
CAS :Hypothemycin, a fungal polyketide, inhibits multiple kinases (VEGFR, MEK, FLT-3, PDGFR, ERK) with Kis ranging from 10 nM to 2.4 μM.Formule :C19H22O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :378.37CLM3
CAS :CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.Formule :C21H21N5Couleur et forme :SolidMasse moléculaire :343.43EGFR-IN-17
EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.Formule :C27H31ClN7O3PCouleur et forme :SolidMasse moléculaire :568.01EGFR-IN-139
CAS :EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Formule :C27H25ClN2O4Couleur et forme :SolidMasse moléculaire :476.951DA-0157
CAS :DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.Formule :C31H43BrN7O2PCouleur et forme :SolidMasse moléculaire :656.597FGFR4-IN-9
FGFR4-IN-9 is a selective inhibitor of FGFR4 (IC50: 75.3 nM) that effectively inhibits the growth and angiogenesis of hepatocellular carcinoma cells.Formule :C24H22ClF3N4O4Couleur et forme :SolidMasse moléculaire :522.9Lucitanib dihydrochloride
CAS :Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient VEGFR1-3, FGFR1-3, and PDGFRalpha/β inhibitor, used in metastatic breast cancer research.Formule :C26H27Cl2N3O4Couleur et forme :SolidMasse moléculaire :516.42Cenacitinib
CAS :Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Formule :C19H19F2N7O3Couleur et forme :SolidMasse moléculaire :431.40EGFR-IN-146
CAS :EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.Formule :C20H16N4Couleur et forme :SolidMasse moléculaire :312.368Pyk2-IN-2
CAS :Pyk2-IN-2 (compound 13j) acts as a Pyk2 inhibitor, exhibiting an IC 50 value of 0.608 μM for FAK kinase [1].Formule :C27H27N7OCouleur et forme :SolidMasse moléculaire :465.55FGFR4-IN-6
FGFR4-IN-6: covalent, reversible FGFR4 blocker, 5.4 nM IC50, good oral bioavailability, reduces Hep3B2.1-7 tumors in mice, low toxicity.Formule :C31H33N7O4Couleur et forme :SolidMasse moléculaire :567.64LSD1/EGFR-IN-1
CAS :LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.
Formule :C21H20ClN3O4Couleur et forme :SolidMasse moléculaire :413.854Multi-kinase-IN-1
CAS :Multi-kinase-IN-1, a powerful kinase inhibitor, exhibits antitumor properties by inducing cell apoptosis.Formule :C35H36F2N6O6SCouleur et forme :SolidMasse moléculaire :706.76EGFR/HER2-IN-6
EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.Formule :C18H21N5O3SCouleur et forme :SolidMasse moléculaire :387.46JAK3/BTK-IN-3
CAS :JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.Formule :C22H28N8OCouleur et forme :SolidMasse moléculaire :420.51BTK-IN-7
BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.Formule :C30H32N6O4Couleur et forme :SolidMasse moléculaire :540.61(R)-9b
CAS :(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.Formule :C20H27ClN6OCouleur et forme :SolidMasse moléculaire :402.92CDDD11-8
CAS :CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].Formule :C24H26N6Couleur et forme :SolidMasse moléculaire :398.50FAK-IN-21
CAS :FAK-IN-21 (compound 9) is a FAK inhibitor with an IC50 value of 37.52 nM. It inhibits cell growth and the phosphorylation of FAK, making it useful for research into diffuse gastric cancer.Formule :C22H22F2N8O3SCouleur et forme :SolidMasse moléculaire :516.52EGFR-IN-18
EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).Formule :C33H28N6O3SCouleur et forme :SolidMasse moléculaire :588.68JNJ-47117096
CAS :JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.Formule :C21H22N4O2Couleur et forme :SolidMasse moléculaire :362.425EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Formule :C30H35FN6O3Couleur et forme :SolidMasse moléculaire :546.64EGFR-IN-62
EGFR-IN-62: IC50 of 10-242 nM for various EGFR mutations, blocks A549/H1975 cell cycle, induces apoptosis, and inhibits cell motility and proliferation.Formule :C30H33N9O2Couleur et forme :SolidMasse moléculaire :551.64PF-06463922 acetate
CAS :PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.Formule :C23H23FN6O4Couleur et forme :SolidMasse moléculaire :466.46EGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Formule :C27H25N3O6SCouleur et forme :SolidMasse moléculaire :519.57(3S,4R)-Tofacitinib
CAS :(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37Lomonitinib
CAS :Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.
Formule :C27H24N4O2Couleur et forme :SolidMasse moléculaire :436.505Milpecitinib
CAS :Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.
Formule :C20H20N4O2SCouleur et forme :SolidMasse moléculaire :380.463FGFR1 inhibitor-6
FGFR1 inhibitor-6, IC50: 16.31 nM, blocks cell cycle at pro-G1/G2/M and induces apoptosis.Formule :C27H19N5O4S2Couleur et forme :SolidMasse moléculaire :541.6HER2-IN-6
CAS :HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)Formule :C26H32N8O3Couleur et forme :SolidMasse moléculaire :504.58JAK-IN-23
"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."Formule :C23H22Cl2N4OCouleur et forme :SolidMasse moléculaire :441.35BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formule :C28H24FN5O2Couleur et forme :SolidMasse moléculaire :481.52Multi-kinase inhibitor 3
CAS :Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.Formule :C26H26N6O2Couleur et forme :SolidMasse moléculaire :454.52EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Couleur et forme :SolidFGFR-IN-6
CAS :FGFR-IN-6 (Compound 5) is an FGFR inhibitor.Formule :C23H22N6O3Couleur et forme :SolidMasse moléculaire :430.46EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Formule :C26H27ClN6O2Couleur et forme :SolidMasse moléculaire :490.98MK-8457
CAS :MK-8457 is a dual inhibitor of SYK and ZAP70, valuable for rheumatoid arthritis research [1].Formule :C24H25F3N4O3SCouleur et forme :SolidMasse moléculaire :506.54Bayer-18
CAS :Bayer-18 is an inhibitor of TYK2. It inhibits the viability of anaplastic large cell lymphoma cells, including K299, SR786, Mac1, and Mac2a, with an IC50 ranging from 2-3 µM. Additionally, Bayer-18 induces apoptosis in K299 and SR786 cells.Formule :C19H27FN6O2Couleur et forme :SolidMasse moléculaire :390.46YSY01A
CAS :YSY01A is a proteasome inhibitor that suppresses cancer cell survival by inducing apoptosis (Apoptosis). It demonstrates IC50 values against various cell lines such as HEK293T, A549, MCF-7, MGC-803, and PC-3M with values of 51.01, 9.21, 5.21, 8.9, and 35.4 nM respectively. Additionally, YSY01A serves as a degrader of gp130 and JAK2, eliminating constitutive STAT3 signaling in human A549 lung cancer cells by downregulating gp130 and JAK2. YSY01A holds potential for research in cancer therapeutics.Formule :C29H38BN5O5Couleur et forme :SolidMasse moléculaire :547.45JAK3-IN-7
CAS :JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFormule :C17H20N6ODegré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :324.38FGFR4-IN-4
CAS :FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.Formule :C28H32Cl2N6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :603.5Sacibertinib
CAS :Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Formule :C32H31ClN6O4Couleur et forme :SolidMasse moléculaire :599.08GLPG3312
CAS :GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .Formule :C23H21F2N5O3Degré de pureté :98.53%Couleur et forme :SolidMasse moléculaire :453.44LT-850-166
LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.Formule :C30H29Cl2N7OCouleur et forme :SolidMasse moléculaire :574.5OXA-11
CAS :OXA-11 (FAK-IN-16) is a FAK inhibitor with anti-tumor activity, useful for cancer research.Formule :C37H49F3N7O5PDegré de pureté :98.70% - 99.20%Couleur et forme :SolidMasse moléculaire :759.8Protein kinase inhibitor 10
CAS :Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9 μM, 13.6 μM, and 2.41 μM for TAM receptors, FAK, and KIT, respectively. It can inhibit abnormal and excessive cell proliferation, showing potential for research in the field of cancer treatment.Formule :C14H9FN6S2Couleur et forme :SolidMasse moléculaire :344.39ES-072
CAS :ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.Formule :C25H27F3N8O2Couleur et forme :SolidMasse moléculaire :528.53FAK inhibitor 7
CAS :FAK inhibitor7, a potent FAK inhibitor, demonstrates an IC50 of 3.58 nM. This compound effectively inhibits downstream signaling cascades of FAK (such as Src and AKT), which leads to cell cycle arrest at the G0/G1 phase and induces cytotoxic autophagy in ovarian cancer cells. Additionally, FAK inhibitor7 has been shown to suppress tumor metastasis and growth in ovarian cancer mouse models.Formule :C32H37N7O3Couleur et forme :SolidMasse moléculaire :567.68FAK-IN-23
CAS :FAK-IN-23 (Compound II) is an inhibitor of focal adhesion kinase (FAK).Formule :C32H38F3N5O8Couleur et forme :SolidMasse moléculaire :677.668VEGFR-2-IN-65
CAS :VEGFR-2-IN-65 (Compound 07) functions as a VEGFR-2 inhibitor. It forms hydrogen bonds with Cys180 and can inhibit tube formation in HUVECs.Formule :C21H18N2O3Couleur et forme :SolidMasse moléculaire :346.379NDI-034858
CAS :NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseasesFormule :C23H24N8O3Degré de pureté :>99.99%Couleur et forme :SolidMasse moléculaire :460.49Vatalanib hydrochloride
CAS :Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.Formule :C20H16Cl2N4Degré de pureté :99.7%Couleur et forme :SolidMasse moléculaire :383.27JDTic
CAS :JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formule :C28H39N3O3Couleur et forme :SolidMasse moléculaire :465.63JAK2-IN-7
CAS :JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Formule :C26H33N7ODegré de pureté :99.54%Couleur et forme :SolidMasse moléculaire :459.59Ref: TM-T35900
1mg145,00€5mg354,00€10mg630,00€25mg1.301,00€50mg1.738,00€100mg2.357,00€1mL*10mM (DMSO)358,00€XMD-17-51 Trifluoroacetate
CAS :XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases.Formule :C23H25F3N8O3Degré de pureté :99.65%Couleur et forme :SolidMasse moléculaire :518.49Ibrutinib Racemate
CAS :Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Formule :C25H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :440.5HMBD-001
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.
Couleur et forme :Odour LiquidNimotuzumab (powder)
CAS :Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.
Couleur et forme :Liquid(3R,4S)-Tofacitinib
CAS :(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37ENMD-2076 tartrate
CAS :ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.Formule :C25H31N7O6Couleur et forme :SolidMasse moléculaire :525.56TLC9995-0188
CAS :Tyrosine-protein kinase ABL, IC50: 1500 nMFormule :C16H15N5Couleur et forme :Yellow SolidMasse moléculaire :277.331Dihydrodiol-Ibrutinib
CAS :PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Formule :C25H26N6O4Couleur et forme :SolidMasse moléculaire :474.521XMU-MP-3
CAS :XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.Formule :C27H27F3N8OCouleur et forme :SolidMasse moléculaire :536.563PM-8002
PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.
Couleur et forme :Odour LiquidImbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Couleur et forme :Odour LiquidDesidustat
CAS :Desidustat is an inhibitor of HIF hydroxylase.
Formule :C16H16N2O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :332.31Ref: TM-T5176
Produit arrêtéOlmutinib
CAS :Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormule :C26H26N6O2SDegré de pureté :99.14%Couleur et forme :SolidMasse moléculaire :486.59Duligotuzumab
CAS :Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.
Degré de pureté :95%Couleur et forme :Liquid3,3',4,4'-Tetrabromobiphenyl
CAS :Produit contrôléApplications 3,3',4,4'-Tetrabromobiphenyl is multi-persistent organic pollutants analyzed in breast milk of first time mothers. An environmental pollutant that affects copper and molybdenum metabolism in rats. Also, it is derived from 1-Bromo-2- nitrobenze (B686175), which is an organic building block used for the synthesis of various pharmaceutical compounds. It is an intermediate for the synthesis of novel Diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.
References Tlustos, C., et al.: Organohalogen Compd., 75, 1185-1188 (2013); Salman, K. N., et al.: Environ. Sci. Pollut. R., 21, 6400-6409 (2014); Dao, P., et al.: Bioorg. Med. Chem. Lett., 23, 4552 (2013);Formule :C12H6Br4Couleur et forme :Off-White To Light BrownMasse moléculaire :469.79VEGFR-IN-1
CAS :VEGFR inhibitorFormule :C19H16ClN3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :337.8
